dpp 4 and glp 1 The Role of GLP-1, DPP-4, SGLT-2 Inhibitors in Diabetes Management Insight into Structure Activity Relationship

A planned Phase I safety trial of 42 healthy volunteers receiving oral BPC-157 was conducted in 2015, but results were never formally published following cancellation of planned submission in 2016

But for raw efficacy, metabolic transformation, and body recomposition, Retatrutide is the clear winner based on current evidence

Ipamorelin hits the GHRP receptor and says "release GH now." CJC-1295 (no DAC) hits the GHRH receptor and says "amplify that release." When dosed together: CJC-1295 primes the pituitary and increases the available pool of GH Ipamorelin triggers the acute release of that pool The combined pulse is substantially larger than either compound generates alone research suggests synergistic effects in the range of 210x depending on baseline GH status and dosing This works because the two compounds bind to completely separate receptors

Retatrutide is a triple-receptor agonist targeting GLP-1, GIP, and glucagon pathways simultaneously, producing an average of 24.2% body weight reduction in Phase 2 clinical trials at the 12mg dose

Glutathione reduces the oxidative stress that would otherwise shorten the effective window of B12s neurological benefits